PMID- 21458093
OWN - NLM
STAT- MEDLINE
DCOM- 20110922
LR  - 20220318
IS  - 1879-0887 (Electronic)
IS  - 0167-8140 (Linking)
VI  - 99
IP  - 1
DP  - 2011 Apr
TI  - FET-PET for malignant glioma treatment planning.
PG  - 44-8
LID - 10.1016/j.radonc.2011.03.001 [doi]
AB  - BACKGROUND AND PURPOSE: The aim of this study was to compare MRI-based 
      morphological gross tumour volumes (GTVs) to biological tumour volumes (BTVs), 
      defined by the pathological radiotracer uptake in positron emission tomography 
      (PET) imaging with (18)F-fluoroethyltyrosine (FET), subsequently clinical target 
      volumes (CTVs) and finally planning target volumes (PTVs) for radiotherapy 
      planning of glioblastoma. PATIENTS AND METHODS: Seventeen patients with 
      glioblastoma were included into a retrospective protocol. Treatment-planning was 
      performed using clinical target volume (CTV=BTV+20mm or CTV=GTV+20mm+inclusion of 
      the edema) and planning target volume (PTV=CTV+5mm). Image fusion and target 
      volume delineation were performed with OTP-Masterplan(R). Initial gross tumour 
      volume (GTV) definition was based on MRI data only or FET-PET data only (BTV), 
      secondarily both data sets were used to define a common CTV. RESULTS: FET based 
      BTVs (median 43.9 cm(3)) were larger than corresponding GTVs (median 34.1cm(3), 
      p=0.028), in 11 of 17 cases there were major differences between GTV/BTV. To 
      evaluate the conformity of both planning methods, the index 
      (CTV(MRT) intersectionCTV(FET))/(CTV(MRT) union or logical sumCTV(FET)) was quantified which was significantly 
      different from 1 (0.73 +/- 0.03, p<0.001). CONCLUSION: With FET-PET-CT planning, 
      the size and geometrical location of GTVs/BTVs differed in a majority of 
      patients. It remains open whether FET-PET-based target definition has a relevant 
      clinical impact for treatment planning.
CI  - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - Niyazi, Maximilian
AU  - Niyazi M
AD  - Department of Radiation Oncology, Ludwig-Maximilians-University Munich, Munchen, 
      Germany. maximilian.niyazi@med.uni-muenchen.de
FAU - Geisler, Julia
AU  - Geisler J
FAU - Siefert, Axel
AU  - Siefert A
FAU - Schwarz, Silke Birgit
AU  - Schwarz SB
FAU - Ganswindt, Ute
AU  - Ganswindt U
FAU - Garny, Sylvia
AU  - Garny S
FAU - Schnell, Oliver
AU  - Schnell O
FAU - Suchorska, Bogdana
AU  - Suchorska B
FAU - Kreth, Friedrich-Wilhelm
AU  - Kreth FW
FAU - Tonn, Jorg-Christian
AU  - Tonn JC
FAU - Bartenstein, Peter
AU  - Bartenstein P
FAU - la Fougere, Christian
AU  - la Fougere C
FAU - Belka, Claus
AU  - Belka C
LA  - eng
PT  - Journal Article
DEP - 20110330
PL  - Ireland
TA  - Radiother Oncol
JT  - Radiotherapy and oncology : journal of the European Society for Therapeutic 
      Radiology and Oncology
JID - 8407192
RN  - 0 (Contrast Media)
RN  - 0 (Radiopharmaceuticals)
RN  - 1326R5J1IA ((18F)fluoroethyltyrosine)
RN  - 42HK56048U (Tyrosine)
SB  - IM
MH  - Aged
MH  - Biopsy
MH  - Brain Neoplasms/diagnostic imaging/pathology/*radiotherapy
MH  - Contrast Media
MH  - Female
MH  - Glioma/*diagnostic imaging/pathology/*radiotherapy
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Positron-Emission Tomography
MH  - *Radiopharmaceuticals
MH  - Radiotherapy Planning, Computer-Assisted/*methods
MH  - Radiotherapy, Conformal
MH  - Retrospective Studies
MH  - Statistics, Nonparametric
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
MH  - Tyrosine/*analogs & derivatives
EDAT- 2011/04/05 06:00
MHDA- 2011/09/23 06:00
CRDT- 2011/04/05 06:00
PHST- 2010/09/25 00:00 [received]
PHST- 2011/02/28 00:00 [revised]
PHST- 2011/03/10 00:00 [accepted]
PHST- 2011/04/05 06:00 [entrez]
PHST- 2011/04/05 06:00 [pubmed]
PHST- 2011/09/23 06:00 [medline]
AID - S0167-8140(11)00122-8 [pii]
AID - 10.1016/j.radonc.2011.03.001 [doi]
PST - ppublish
SO  - Radiother Oncol. 2011 Apr;99(1):44-8. doi: 10.1016/j.radonc.2011.03.001. Epub 
      2011 Mar 30.